235,813 Shares in BridgeBio Pharma, Inc. $BBIO Purchased by SEB Asset Management AB

Posted by George Bondi on Jul 21st, 2026

SEB Asset Management AB bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 235,813 shares of the company’s stock, valued at approximately $17,511,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of BBIO. Harvest Fund Management Co. Ltd acquired a new stake in BridgeBio Pharma during the 3rd quarter valued at approximately $34,000. Jones Financial Companies Lllp purchased a new stake in shares of BridgeBio Pharma in the 1st quarter valued at $35,000. Farther Finance Advisors LLC increased its stake in shares of BridgeBio Pharma by 91.4% in the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock worth $39,000 after acquiring an additional 245 shares during the period. Global Retirement Partners LLC increased its stake in shares of BridgeBio Pharma by 271.5% in the fourth quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock worth $39,000 after acquiring an additional 372 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of BridgeBio Pharma during the fourth quarter worth $41,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma Price Performance

BBIO opened at $80.76 on Tuesday. The firm has a fifty day moving average price of $71.46 and a 200 day moving average price of $72.33. BridgeBio Pharma, Inc. has a 1 year low of $42.09 and a 1 year high of $93.42. The stock has a market cap of $15.82 billion, a P/E ratio of -21.59 and a beta of 0.95.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The company had revenue of $194.51 million for the quarter, compared to the consensus estimate of $178.07 million. The business’s revenue for the quarter was up 66.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.88) EPS. Equities analysts expect that BridgeBio Pharma, Inc. will post -2.29 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on BBIO shares. Royal Bank Of Canada started coverage on shares of BridgeBio Pharma in a research report on Thursday, April 9th. They set an “outperform” rating and a $100.00 target price for the company. Raymond James Financial downgraded BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 26th. Truist Financial lifted their price objective on BridgeBio Pharma from $95.00 to $102.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Canaccord Genuity Group began coverage on BridgeBio Pharma in a report on Wednesday, June 3rd. They issued a “buy” rating and a $104.00 price objective for the company. Finally, Mizuho lowered their target price on BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 16th. Twenty analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $95.21.

Check Out Our Latest Analysis on BBIO

Insiders Place Their Bets

In other news, Director Andrea Ellis sold 17,167 shares of the stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $84.00, for a total transaction of $1,442,028.00. Following the sale, the director directly owned 22,579 shares of the company’s stock, valued at $1,896,636. This represents a 43.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Randal W. Scott sold 10,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $67.15, for a total value of $671,500.00. Following the sale, the director owned 11,589 shares in the company, valued at $778,201.35. This trade represents a 46.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 432,117 shares of company stock valued at $32,633,740. Insiders own 14.23% of the company’s stock.

BridgeBio Pharma Profile

(Free Report)

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.